drugset

drugset / Trial / NCT02264613

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613 ↗

Phase 1/2 Completed 142 enrolled Aileron Therapeutics, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Timeline

Start: 2014-10
Primary completion: 2020-03
Completion: 2020-04

Publications

Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, Zhan Y, Oliveira MMS, Westerberg LS, Annis DA, Johnsen JI, Selivanova G. Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. Cancer Discov. 2021 Dec 1;11(12):3090-3105. doi: 10.1158/2159-8290.CD-20-1741.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SULANEMADLIN	Peptide	—	Intravenous

Indications